Review
BibTex RIS Cite

The Role of Colchicine and Potential Medicinal Plants in the Treatment of Familial Mediterranean Fever

Year 2023, , 119 - 142, 15.04.2023
https://doi.org/10.38001/ijlsb.1198033

Abstract

Familial Mediterranean Fever; it is a congenital antiinflammatory disease that effects the immune system, inheriting an autosomal recessive gene. The disease is observed as a result of mutation in the MEFV gene on chromosome 16. It is a disease that progresses with recurrent fever and serositis attacks. The alkaloid named colchicine, obtained from the seeds of the medicinal plant Colchicum autumnale L., is widely used and plays an active role in the treatment of FMF today. Some recent studies provide meaningful data that the combination of herbs Andrographis paniculata Nees., Eleutherococcus senticosus Maxim., Schizandra chinensis Bail., and Glycyrrhiza glabra L. is safe and effective in patients with FMF. Cannabis sativa L. is evaluated as an alternative therapeutic option in mixed FMF cases. In this study, it is aimed to examine in detail colchicine, a natural origin drug substance used in the treatment of FMF, as well as to evaluate other potential medicinal plant species.

References

  • Referans1 Ozen, S., I. Kone-Paut, and A. Gül. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. in Seminars in arthritis and rheumatism. 2017. Elsevier.
  • Referans2 Onen, F., Familial mediterranean fever. Rheumatology international, 2006. 26(6): p. 489-496.
  • Referans3 Çobankara, V. and A. BALKARLI, Ailesel Akdeniz Ateşi. Pamukkale Tıp Dergisi, 2011(2): p. 86-98.
  • Referans4 Lidar, M. and A. Livneh, Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med, 2007. 65(9): p. 318-24.
  • Referans5 Petrushkin, H., et al., Clinical review: familial mediterranean fever—an overview of pathogenesis, symptoms, ocular manifestations, and treatment. Ocular Immunology and Inflammation, 2016. 24(4): p. 422-430.
  • Referans6 Kasapçopur, Ö. and N. ARISOY, Ailesel Akdeniz Ateşi ve diğer otoenflamatuar hastalıklar Derleme. Türk Pediatri Arşivi, 2006. 41(1): p. 9-17.
  • Referans7 Alghamdi, M., Familial Mediterranean fever, review of the literature. Clinical rheumatology, 2017. 36(8): p. 1707-1713.
  • Referans8 Benson, M.D., Amyloidosis. eLS, 2001.
  • Referans9 Lee, A. and H.A. Blair, Anakinra in familial Mediterranean fever: a profile of its use. Drugs & Therapy Perspectives, 2021. 37(3): p. 101-107.
  • Referans10 Tufan, A. and H. LACHMANN, Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turkish Journal of Medical Sciences, 2020. 50(10): p. 1591-1610.
  • Referans11 Ade, R. and M.K. Rai, Colchicine, current advances and future prospects. Nusantara Bioscience, 2010. 2(2).
  • Referans12 Cerquaglia, C., et al., Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Current Drug Targets-Inflammation & Allergy, 2005. 4(1): p. 117-124.
  • Referans13 Grattagliano, I., et al., Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clinical Pharmacology & Therapeutics, 2014. 95(1): p. 89-97.
  • Referans14 Molad, Y., Update on colchicine and its mechanism of action. Current rheumatology reports, 2002. 4(3): p. 252-256.
  • Referans15 Leung, Y.Y., L.L.Y. Hui, and V.B. Kraus. Colchicine—update on mechanisms of action and therapeutic uses. in Seminars in arthritis and rheumatism. 2015. Elsevier.
  • Referans16 Gül, A., Treatment of familial Mediterranean fever: colchicine and beyond. Isr Med Assoc J, 2014. 16(5): p. 281-284.
  • Referans17 Schlesinger, N., B.L. Firestein, and L. Brunetti, Colchicine in COVID-19: an old drug, new use. Current pharmacology reports, 2020. 6(4): p. 137-145.
  • Referans18 Portincasa, P., Colchicine, biologic agents and more for the treatment of familial mediterranean fever. The old, the new, and the rare. Current medicinal chemistry, 2016. 23(1): p. 60-86.
  • Referans19 Joshi, C., E.S. Priya, and C. Mathela, Isolation and anti-inflammatory activity of colchicinoids from Gloriosa superba seeds. Pharmaceutical biology, 2010. 48(2): p. 206-209.
  • Referans20 Rigante, D., et al., The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever. European Review for Medical and Pharmacological Sciences, 2006. 10(4): p. 173.
  • Referans21 Niel, E. and J.-M. Scherrmann, Colchicine today. Joint bone spine, 2006. 73(6): p. 672-678.
  • Referans22 Lidar, M., et al., Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. The Journal of rheumatology, 2003. 30(12): p. 2620-2623.
  • Referans23 Goldbart, A., et al., Near fatal acute colchicine intoxication in a child. A case report. European journal of pediatrics, 2000. 159(12): p. 895-897.
  • Referans24 Bonini, S.A., et al., Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. Journal of ethnopharmacology, 2018. 227: p. 300-315.
  • Referans25 ElSohly, M.A., et al., Phytochemistry of Cannabis sativa L. Phytocannabinoids, 2017: p. 1-36.
  • Referans26 Mastinu, A., et al., Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation. Hormone molecular biology and clinical investigation, 2018. 36(2).
  • Referans27 Habib, G. and U. Levinger, Medical cannabis in treatment of resistant familial Mediterranean fever. The American Journal of Case Reports, 2019. 20: p. 1340.
  • Referans28 Holdcroft, A., et al., Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia, 1997. 52(5): p. 483-486.
  • Referans29 Samy, R.P., M. Thwin, and P. Gopalakrishnakone, Phytochemistry, pharmacology and clinical use of Andrographis paniculata. Natural Product Communications, 2007. 2(5): p. 1934578X0700200519.
  • Referans30 Akbar, S., Andrographis paniculata: a review of pharmacological activities and clinical effects. Alternative Medicine Review, 2011. 16(1): p. 66-77.
  • Referans31 Rao, Y.K., et al., Flavonoids and andrographolides from Andrographis paniculata. Phytochemistry, 2004. 65(16): p. 2317-2321.
  • Referans32 Sharma, A., K. Lal, and S.S. Handa, Standardization of the Indian crude drug Kalmegh by high pressure liquid chromatographic determination of andrographolide. Phytochemical analysis, 1992. 3(3): p. 129-131.
  • Referans33 Madav, S., H. Tripathi, and S. Mishra, Analgesic, antipyretic and antiulcerogenic effects of andrographolide. Indian Journal of Pharmaceutical Sciences, 1995. 57(3): p. 121.
  • Referans34 Panossian, A., et al., Plasma nitric oxide level in familial Mediterranean fever and its modulations by Immuno-Guard. Nitric Oxide, 2003. 9(2): p. 103-110.
  • Referans35 Hossain, S., et al., Andrographis paniculata (Burm. f.) Wall. ex Nees: An Updated Review of Phytochemistry, Antimicrobial Pharmacology, and Clinical Safety and Efficacy. Life, 2021. 11(4): p. 348.
  • Referans36 Bone, K., M. Simon Mills, and M. Fnimh, Principles and practice of phytotherapy: modern herbal medicine. 2012: Elsevier Health Sciences.
  • Referans37 Amaryan, G., et al., Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard®–a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean Fever. Phytomedicine, 2003. 10(4): p. 271-285.
  • Referans38 Kaur, R., H. Kaur, and A.S. Dhindsa, Glycyrrhiza glabra: a phytopharmacological review. International journal of pharmaceutical Sciences and Research, 2013. 4(7): p. 2470.
  • Referans39 Sun, Y.-L., L.-D. Liu, and S.-K. Hong, Eleutherococcus senticosus as a crude medicine: Review of biological and pharmacological effects. Journal of Medicinal Plants Research, 2011. 5(25): p. 5946-5952.
  • Referans40 Davydov, M. and A.D. Krikorian, Eleutherococcus senticosus (Rupr. & Maxim.) Maxim.(Araliaceae) as an adaptogen: a closer look. Journal of ethnopharmacology, 2000. 72(3): p. 345-393.
  • Referans41 Hancke, J., R. Burgos, and F. Ahumada, Schisandra chinensis (Turcz.) baill. Fitoterapia, 1999. 70(5): p. 451-471.
  • Referans42 Mocan, A., et al., Comparative studies on polyphenolic composition, antioxidant and antimicrobial activities of Schisandra chinensis leaves and fruits. Molecules, 2014. 19(9): p. 15162-15179.
  • Referans43 Zhao, T., et al., Antitumor and immunomodulatory activity of a water-soluble low molecular weight polysaccharide from Schisandra chinensis (Turcz.) Baill. Food and chemical toxicology, 2013. 55: p. 609-616.
  • Referans44 Guo, L.Y., et al., Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. European journal of pharmacology, 2008. 591(1-3): p. 293-299.
  • Referans45 Kang, S., et al., Identification of a novel anti-inflammatory compound, α-cubebenoate from Schisandra chinensis. Journal of ethnopharmacology, 2014. 153(1): p. 242-249.
  • Referans46 Saruwatari, J., et al., The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. Journal of pharmacy and pharmacology, 2003. 55(11): p. 1553-1559.
  • Referans47 Ashour, M.L. and M. Wink, Genus Bupleurum: a review of its phytochemistry, pharmacology and modes of action. Journal of pharmacy and pharmacology, 2011. 63(3): p. 305-321.
  • Referans48 Yang, F., et al., Radix Bupleuri: a review of traditional uses, botany, phytochemistry, pharmacology, and toxicology. BioMed Research International, 2017. 2017.
  • Referans49 Coon, J.T. and E. Ernst, Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf, 2002. 25(5): p. 323-44.
  • Referans50 CHOI, K.t., Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng CA Meyer. Acta Pharmacologica Sinica, 2008. 29(9): p. 1109-1118.
  • Referans51 Ernst, E., Panax ginseng: an overview of the clinical evidence. Journal of Ginseng Research, 2010. 34(4): p. 259-263.
  • Referans52 Wu, Y.-Y., et al., Chemical constituents from the tubers of Pinellia ternata (Araceae) and their chemotaxonomic interest. Biochemical Systematics and Ecology, 2015. 62: p. 236-240.
  • Referans53 Mao, R. and Z. He, Pinellia ternata (Thunb.) Breit: a review of its germplasm resources, genetic diversity and active components. Journal of Ethnopharmacology, 2020. 263: p. 113252.
  • Referans54 Zhao, T., et al., Scutellaria baicalensis Georgi.(Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Journal of Pharmacy and Pharmacology, 2019. 71(9): p. 1353-1369.
  • Referans55 HÜRKAN, Y.K., Hünnap (Ziziphus jujuba Mill.) meyvesi: Geçmişten günümüze tıbbi önemi. Journal of the Institute of Science and Technology, 2019. 9(3): p. 1271-1281.
  • Referans56 Mahajan, R. and M. Chopda, Phyto-Pharmacology of Ziziphus jujuba Mill-A plant review. Pharmacognosy Reviews, 2009. 3(6): p. 320.
  • Referans57 Choi, S.-H., et al., Distribution of free amino acids, flavonoids, total phenolics, and antioxidative activities of jujube (Ziziphus jujuba) fruits and seeds harvested from plants grown in Korea. Journal of agricultural and food chemistry, 2011. 59(12): p. 6594-6604.
  • Referans58 Ali, B.H., et al., Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food and chemical Toxicology, 2008. 46(2): p. 409-420.
  • Referans59 Kuete, V., Medicinal spices and vegetables from Africa: therapeutic potential against metabolic, inflammatory, infectious and systemic diseases. 2017: Academic Press.
  • Referans60 Aktaş, T. and H. Çölgeçen, Farklı bitki türlerinden bitki doku kültürü teknikleriyle flavonoidlerin üretimi. Karaelmas Fen ve Mühendislik Dergisi, 2017. 7(2): p. 665-673.
  • Referans61 Al-Snafi, A.E., Glycyrrhiza glabra: A phytochemical and pharmacological review. IOSR Journal of Pharmacy, 2018. 8(6): p. 1-17.
  • Referans62 Shimizu, I., Sho‐saiko‐to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. Journal of gastroenterology and hepatology, 2000. 15: p. 84-90.
  • Referans63 Komatsu, M., et al., Familial Mediterranean fever medicated with an herbal medicine in Japan. Pediatrics international, 2004. 46(1): p. 81-84.
  • Referans64 Tsuchiya-Suzuki, A., et al., Clinical and genetic features of familial Mediterranean fever in Japan. The Journal of Rheumatology, 2009. 36(8): p. 1671-1676.

Ailevi Akdeniz Ateşi Hastalığı’nın Tedavisinde Kolşisin’in Yeri Ve Potansiyel Tıbbi Bitkiler

Year 2023, , 119 - 142, 15.04.2023
https://doi.org/10.38001/ijlsb.1198033

Abstract

Ailevi Akdeniz Ateşi; otozomal resesif genin kalıtımıyla, doğuştan gelen ve immün sistemi etkileyen bir antiinflamatuvar hastalıktır. Hastalık, 16. kromozomdaki MEFV geninde oluşan mutasyon sonucu gözlenir. Tekrarlayan ateş ve serözit ataklarla seyreden bir hastalıktır. Colchicum autumnale L. isimli tıbbi bitkinin tohumlarından elde edilen kolşisin isimli alkaloid günümüzde AAA tedavisinde yaygın olarak kullanılmakta ve etkin bir rol oynamaktadır. Yakın zamanlı bazı araştırmalar Andrographis paniculata Nees., Eleutherococcus senticosus Maxim., Schizandra chinensis Bail., and Glycyrrhiza glabra L. bitki kombinasyonun AAA hastalarında güvenli ve etkili olduğuna dair anlamlı veriler sunmaktadır. Cannabis sativa L. ise karışık AAA olgularında alternatif bir terapötik seçenek olarak değerlendirmektedir. Bu çalışmada AAA tedavisinde kullanılan doğal kökenli bir ilaç etkin maddesi olan kolşisinin detaylı incelenmesi ile bunun yanı sıra diğer potansiyel tıbbi bitki türlerinin değerlendirilmesi amaçlanmaktadır.

References

  • Referans1 Ozen, S., I. Kone-Paut, and A. Gül. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. in Seminars in arthritis and rheumatism. 2017. Elsevier.
  • Referans2 Onen, F., Familial mediterranean fever. Rheumatology international, 2006. 26(6): p. 489-496.
  • Referans3 Çobankara, V. and A. BALKARLI, Ailesel Akdeniz Ateşi. Pamukkale Tıp Dergisi, 2011(2): p. 86-98.
  • Referans4 Lidar, M. and A. Livneh, Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med, 2007. 65(9): p. 318-24.
  • Referans5 Petrushkin, H., et al., Clinical review: familial mediterranean fever—an overview of pathogenesis, symptoms, ocular manifestations, and treatment. Ocular Immunology and Inflammation, 2016. 24(4): p. 422-430.
  • Referans6 Kasapçopur, Ö. and N. ARISOY, Ailesel Akdeniz Ateşi ve diğer otoenflamatuar hastalıklar Derleme. Türk Pediatri Arşivi, 2006. 41(1): p. 9-17.
  • Referans7 Alghamdi, M., Familial Mediterranean fever, review of the literature. Clinical rheumatology, 2017. 36(8): p. 1707-1713.
  • Referans8 Benson, M.D., Amyloidosis. eLS, 2001.
  • Referans9 Lee, A. and H.A. Blair, Anakinra in familial Mediterranean fever: a profile of its use. Drugs & Therapy Perspectives, 2021. 37(3): p. 101-107.
  • Referans10 Tufan, A. and H. LACHMANN, Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turkish Journal of Medical Sciences, 2020. 50(10): p. 1591-1610.
  • Referans11 Ade, R. and M.K. Rai, Colchicine, current advances and future prospects. Nusantara Bioscience, 2010. 2(2).
  • Referans12 Cerquaglia, C., et al., Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Current Drug Targets-Inflammation & Allergy, 2005. 4(1): p. 117-124.
  • Referans13 Grattagliano, I., et al., Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clinical Pharmacology & Therapeutics, 2014. 95(1): p. 89-97.
  • Referans14 Molad, Y., Update on colchicine and its mechanism of action. Current rheumatology reports, 2002. 4(3): p. 252-256.
  • Referans15 Leung, Y.Y., L.L.Y. Hui, and V.B. Kraus. Colchicine—update on mechanisms of action and therapeutic uses. in Seminars in arthritis and rheumatism. 2015. Elsevier.
  • Referans16 Gül, A., Treatment of familial Mediterranean fever: colchicine and beyond. Isr Med Assoc J, 2014. 16(5): p. 281-284.
  • Referans17 Schlesinger, N., B.L. Firestein, and L. Brunetti, Colchicine in COVID-19: an old drug, new use. Current pharmacology reports, 2020. 6(4): p. 137-145.
  • Referans18 Portincasa, P., Colchicine, biologic agents and more for the treatment of familial mediterranean fever. The old, the new, and the rare. Current medicinal chemistry, 2016. 23(1): p. 60-86.
  • Referans19 Joshi, C., E.S. Priya, and C. Mathela, Isolation and anti-inflammatory activity of colchicinoids from Gloriosa superba seeds. Pharmaceutical biology, 2010. 48(2): p. 206-209.
  • Referans20 Rigante, D., et al., The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever. European Review for Medical and Pharmacological Sciences, 2006. 10(4): p. 173.
  • Referans21 Niel, E. and J.-M. Scherrmann, Colchicine today. Joint bone spine, 2006. 73(6): p. 672-678.
  • Referans22 Lidar, M., et al., Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. The Journal of rheumatology, 2003. 30(12): p. 2620-2623.
  • Referans23 Goldbart, A., et al., Near fatal acute colchicine intoxication in a child. A case report. European journal of pediatrics, 2000. 159(12): p. 895-897.
  • Referans24 Bonini, S.A., et al., Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. Journal of ethnopharmacology, 2018. 227: p. 300-315.
  • Referans25 ElSohly, M.A., et al., Phytochemistry of Cannabis sativa L. Phytocannabinoids, 2017: p. 1-36.
  • Referans26 Mastinu, A., et al., Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation. Hormone molecular biology and clinical investigation, 2018. 36(2).
  • Referans27 Habib, G. and U. Levinger, Medical cannabis in treatment of resistant familial Mediterranean fever. The American Journal of Case Reports, 2019. 20: p. 1340.
  • Referans28 Holdcroft, A., et al., Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia, 1997. 52(5): p. 483-486.
  • Referans29 Samy, R.P., M. Thwin, and P. Gopalakrishnakone, Phytochemistry, pharmacology and clinical use of Andrographis paniculata. Natural Product Communications, 2007. 2(5): p. 1934578X0700200519.
  • Referans30 Akbar, S., Andrographis paniculata: a review of pharmacological activities and clinical effects. Alternative Medicine Review, 2011. 16(1): p. 66-77.
  • Referans31 Rao, Y.K., et al., Flavonoids and andrographolides from Andrographis paniculata. Phytochemistry, 2004. 65(16): p. 2317-2321.
  • Referans32 Sharma, A., K. Lal, and S.S. Handa, Standardization of the Indian crude drug Kalmegh by high pressure liquid chromatographic determination of andrographolide. Phytochemical analysis, 1992. 3(3): p. 129-131.
  • Referans33 Madav, S., H. Tripathi, and S. Mishra, Analgesic, antipyretic and antiulcerogenic effects of andrographolide. Indian Journal of Pharmaceutical Sciences, 1995. 57(3): p. 121.
  • Referans34 Panossian, A., et al., Plasma nitric oxide level in familial Mediterranean fever and its modulations by Immuno-Guard. Nitric Oxide, 2003. 9(2): p. 103-110.
  • Referans35 Hossain, S., et al., Andrographis paniculata (Burm. f.) Wall. ex Nees: An Updated Review of Phytochemistry, Antimicrobial Pharmacology, and Clinical Safety and Efficacy. Life, 2021. 11(4): p. 348.
  • Referans36 Bone, K., M. Simon Mills, and M. Fnimh, Principles and practice of phytotherapy: modern herbal medicine. 2012: Elsevier Health Sciences.
  • Referans37 Amaryan, G., et al., Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard®–a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean Fever. Phytomedicine, 2003. 10(4): p. 271-285.
  • Referans38 Kaur, R., H. Kaur, and A.S. Dhindsa, Glycyrrhiza glabra: a phytopharmacological review. International journal of pharmaceutical Sciences and Research, 2013. 4(7): p. 2470.
  • Referans39 Sun, Y.-L., L.-D. Liu, and S.-K. Hong, Eleutherococcus senticosus as a crude medicine: Review of biological and pharmacological effects. Journal of Medicinal Plants Research, 2011. 5(25): p. 5946-5952.
  • Referans40 Davydov, M. and A.D. Krikorian, Eleutherococcus senticosus (Rupr. & Maxim.) Maxim.(Araliaceae) as an adaptogen: a closer look. Journal of ethnopharmacology, 2000. 72(3): p. 345-393.
  • Referans41 Hancke, J., R. Burgos, and F. Ahumada, Schisandra chinensis (Turcz.) baill. Fitoterapia, 1999. 70(5): p. 451-471.
  • Referans42 Mocan, A., et al., Comparative studies on polyphenolic composition, antioxidant and antimicrobial activities of Schisandra chinensis leaves and fruits. Molecules, 2014. 19(9): p. 15162-15179.
  • Referans43 Zhao, T., et al., Antitumor and immunomodulatory activity of a water-soluble low molecular weight polysaccharide from Schisandra chinensis (Turcz.) Baill. Food and chemical toxicology, 2013. 55: p. 609-616.
  • Referans44 Guo, L.Y., et al., Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. European journal of pharmacology, 2008. 591(1-3): p. 293-299.
  • Referans45 Kang, S., et al., Identification of a novel anti-inflammatory compound, α-cubebenoate from Schisandra chinensis. Journal of ethnopharmacology, 2014. 153(1): p. 242-249.
  • Referans46 Saruwatari, J., et al., The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. Journal of pharmacy and pharmacology, 2003. 55(11): p. 1553-1559.
  • Referans47 Ashour, M.L. and M. Wink, Genus Bupleurum: a review of its phytochemistry, pharmacology and modes of action. Journal of pharmacy and pharmacology, 2011. 63(3): p. 305-321.
  • Referans48 Yang, F., et al., Radix Bupleuri: a review of traditional uses, botany, phytochemistry, pharmacology, and toxicology. BioMed Research International, 2017. 2017.
  • Referans49 Coon, J.T. and E. Ernst, Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf, 2002. 25(5): p. 323-44.
  • Referans50 CHOI, K.t., Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng CA Meyer. Acta Pharmacologica Sinica, 2008. 29(9): p. 1109-1118.
  • Referans51 Ernst, E., Panax ginseng: an overview of the clinical evidence. Journal of Ginseng Research, 2010. 34(4): p. 259-263.
  • Referans52 Wu, Y.-Y., et al., Chemical constituents from the tubers of Pinellia ternata (Araceae) and their chemotaxonomic interest. Biochemical Systematics and Ecology, 2015. 62: p. 236-240.
  • Referans53 Mao, R. and Z. He, Pinellia ternata (Thunb.) Breit: a review of its germplasm resources, genetic diversity and active components. Journal of Ethnopharmacology, 2020. 263: p. 113252.
  • Referans54 Zhao, T., et al., Scutellaria baicalensis Georgi.(Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Journal of Pharmacy and Pharmacology, 2019. 71(9): p. 1353-1369.
  • Referans55 HÜRKAN, Y.K., Hünnap (Ziziphus jujuba Mill.) meyvesi: Geçmişten günümüze tıbbi önemi. Journal of the Institute of Science and Technology, 2019. 9(3): p. 1271-1281.
  • Referans56 Mahajan, R. and M. Chopda, Phyto-Pharmacology of Ziziphus jujuba Mill-A plant review. Pharmacognosy Reviews, 2009. 3(6): p. 320.
  • Referans57 Choi, S.-H., et al., Distribution of free amino acids, flavonoids, total phenolics, and antioxidative activities of jujube (Ziziphus jujuba) fruits and seeds harvested from plants grown in Korea. Journal of agricultural and food chemistry, 2011. 59(12): p. 6594-6604.
  • Referans58 Ali, B.H., et al., Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food and chemical Toxicology, 2008. 46(2): p. 409-420.
  • Referans59 Kuete, V., Medicinal spices and vegetables from Africa: therapeutic potential against metabolic, inflammatory, infectious and systemic diseases. 2017: Academic Press.
  • Referans60 Aktaş, T. and H. Çölgeçen, Farklı bitki türlerinden bitki doku kültürü teknikleriyle flavonoidlerin üretimi. Karaelmas Fen ve Mühendislik Dergisi, 2017. 7(2): p. 665-673.
  • Referans61 Al-Snafi, A.E., Glycyrrhiza glabra: A phytochemical and pharmacological review. IOSR Journal of Pharmacy, 2018. 8(6): p. 1-17.
  • Referans62 Shimizu, I., Sho‐saiko‐to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. Journal of gastroenterology and hepatology, 2000. 15: p. 84-90.
  • Referans63 Komatsu, M., et al., Familial Mediterranean fever medicated with an herbal medicine in Japan. Pediatrics international, 2004. 46(1): p. 81-84.
  • Referans64 Tsuchiya-Suzuki, A., et al., Clinical and genetic features of familial Mediterranean fever in Japan. The Journal of Rheumatology, 2009. 36(8): p. 1671-1676.
There are 64 citations in total.

Details

Primary Language Turkish
Subjects Botany
Journal Section Review Articles
Authors

Tuba Serbetcı 0000-0002-9545-152X

Başak Ceylan 0000-0002-2286-7591

Publication Date April 15, 2023
Published in Issue Year 2023

Cite

EndNote Serbetcı T, Ceylan B (April 1, 2023) Ailevi Akdeniz Ateşi Hastalığı’nın Tedavisinde Kolşisin’in Yeri Ve Potansiyel Tıbbi Bitkiler. International Journal of Life Sciences and Biotechnology 6 1 119–142.


Sosyal ağlarda bizi takip edin   19277 19276 20153 22366